TITLE

Briefly

AUTHOR(S)
Collier, Roger; Kondro, Wayne
PUB. DATE
January 2010
SOURCE
CMAJ: Canadian Medical Association Journal;1/12/2010 Supplement, Vol. 182, pE41
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to health and medicine sector. The U.S. Food and Drug Administration has launched a program to reduce medical mishaps caused by inappropriate medication use. A pair of medical students at the University of Sydney in Australia have offered to sacrifice their starting salaries for a year if they are given public hospital intern positions. A team of cardiologists in U.S. has found that people in ancient times likely had cardiovascular diseases.
ACCESSION #
51229539

 

Related Articles

  • First ARB approved for heart failure.  // Drug Topics;3/7/2005, Vol. 149 Issue 5, p8 

    This article reports that Candesartan has been cleared by the U.S. Food and Drug Administration for the treatment of heart failure, to reduce the risk of death from cardiovascular causes and decrease hospitalizations for heart failure.

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p8 

    The article offers news briefs related to drug development for cardiovascular diseases in the U.S. Angioblast Systems was allowed by the Food and Drug Administration (FDA) to start a phase II clinical trial of its allogeneic adult stem cells for patients with heart attacks. A chronic kidney...

  • Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations. HIRSHBERG, BOAZ; KATZ, ARIE // Diabetes Care;Aug2013 Supplement, Vol. 36 Issue S2, pS253 

    The article discusses the challenges facing the pharmaceutical industry as a result of the U.S. Food and Drug Administration (FDA) guidance on the conduct of cardiovascular (CV) outcome studies with anti-diabetes agents. The guidance provides data to estimate CV risk associated with such agents....

  • FDA Yanks Zelnorm. B. H. // Pharmaceutical Executive;May2007, Vol. 27 Issue 5, p32 

    The article reports on the request of U.S. Food and Drug Administration (FDA) to Novartis AG to pull out Zelnorm from the market due to its potential cardiovascular risks. According to the company that patients with severe cases of irritable bowel snydrome are allowed to take the drug. But,...

  • Fish Oil Now Available By Prescription! Faloon, William // Life Extension;Sep2006, Vol. 12 Issue 9, p7 

    The author comments on pharmaceutical companies taking advantage of U.S. Food and Drug Administration regulations to charge consumers outlandish prices for fish oil drugs. He stated that with prescription drug status, companies can freely make specific health claims about fish oil and...

  • Naloxegol Phase III Win Muted by FDA's CV Stance. Powers, Marie // BioWorld Today;11/13/2012, Vol. 23 Issue 221, p1 

    This article discusses the impact of the U.S. Food and Drug Administration's (FDA) stance toward additional cardiovascular (CV) safety trials for drugs in the class on the positive results of two Phase III studies and a safety extension trial of naloxegol (NKTR-118) in noncancer-related pain and...

  • All Eyes on FDA Safety Guidance. Powers, Marie // BioWorld Today;11/13/2012, Vol. 23 Issue 221, p5 

    This article discusses the impact of the U.S. Food and Drug Administration's (FDA) stance toward additional cardiovascular (CV) safety trials for drugs in the class on the positive results of two Phase III studies and a safety extension trial of naloxegol (NKTR-118) in noncancer-related pain and...

  • Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory Perspective. Joseph BORG, John; TOMASI, Paolo; Luca, Luca; AISLAITNER, George; PIROZYNSKI, Michal; LEUFKENS, Hubert; MELCHIORRI, Daniela // Scientia Pharmaceutica;2014, Vol. 82 Issue 4, p847 

    When an innovative product (innovator) is not covered anymore by intellectual property rights, cheaper equivalent medicinal products (generic products) may be marketed and used in clinical practice. The regulation of generic products is well-established, and is primarily based on standard rules...

  • ADHD: FDA debates black box warnings.  // PharmaWatch: CNS;May2006, Vol. 5 Issue 5, p9 

    The article discusses the possible effects of the recommendation of the U.S. Food and Drug Administration (FDA) on the improved attention-deficit hyperactivity disorder drugs bearing black box warning about the psychiatric and cardiovascular risks in children. While waiting for the FDA's...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics